The PI3K-PDK1 signaling pathway has been linked to CDK4/6 inhibitor resistance, with ribociclib-resistant BC cell lines exhibiting an increase in PDK1 levels after drug exposure, culminating in AKT pathway activation [68]. Here, PIK3CA is linked to breast cancer.